Mineral and Bone Disorder Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The mineral and bone disorder treatment market size has grown strongly in recent years. It will grow from $3.3 billion in 2024 to $3.55 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to chronic kidney disease, aging population, rising awareness of mineral and bone disorders, increased availability of mineral and bone disorder treatments, rising disposable income levels.

The mineral and bone disorder treatment market size is expected to see strong growth in the next few years. It will grow to $4.68 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rising demand for quality of life treatments, growing demand for personalized medicine, government spending on healthcare, rising awareness of the importance of early diagnosis. Major trends in the forecast period include advancements in medical research, pharmaceutical developments, digital health, biologic therapies, telehealth and remote monitoring.

The growing elderly population is expected to drive the growth of the mineral and bone disorder treatment market in the coming years. The elderly population refers to individuals aged 65 and older. As people age, they often experience a loss of muscle and bone mass, which leads to weakness and reduced strength. Mineral and bone treatments can help prevent age-related changes in muscles, bones, and joints, strengthen bones, and slow the progression of bone loss. For example, in July 2024, the UK Parliament's House of Commons Library, a UK-based government agency, reported that in 2022, 12.7 million people in the UK, or 19% of the total population, were aged 65 or older. This number is projected to increase to 22.1 million by 2072, accounting for 27% of the population. As a result, the rising elderly population is fueling the growth of the mineral and bone disorder treatment market.

The rising incidence of chronic kidney diseases is anticipated to drive the growth of the mineral and bone disorder treatment market. Chronic kidney disease (CKD) is characterized by the gradual loss of kidney function over an extended period. Effective treatment of mineral and bone disorders in CKD aims to maintain appropriate mineral balance, preserve bone health, and mitigate the complications associated with these imbalances. As of March 2022, data from the National Library of Medicine, a US-based medical resource, indicates that over 800 million people globally, constituting 10% of the world's population, suffer from chronic kidney disease, a progressive ailment. Consequently, the increasing prevalence of chronic kidney diseases is a key factor propelling the growth of the mineral and bone disorder treatment market.

Prominent companies in the mineral and bone disorder treatment market are strategically focusing on the development and approval of new products to enhance their market position. The increasing prevalence of chronic kidney diseases, particularly among the aging population, has led to the approval of new drugs for mineral and bone disorders. An example of such an approved drug is TYMLOS (abaloparatide), which contains the active drug abaloparatide, a synthetic form of the human parathyroid hormone. For instance, in December 2022, Radius Health Inc., a biopharmaceutical company based in the United States, successfully obtained approval for TYMLOS (abaloparatide). This drug, an analog of parathyroid hormone-related peptide [PTHrP(1-34)], is designed for the treatment of increasing bone density in men with osteoporosis who are at a high risk of fractures. TYMLOS acts as an anabolic agent for bones by selectively activating the parathyroid hormone 1 receptor (PTH1R) expressed in osteoblasts and osteocytes, resulting in enhanced bone formation and density.

In May 2023, Abiogen Pharma Spa, an Italian pharmaceutical company, acquired EffRx Pharmaceuticals SA for $8.77 million. This strategic acquisition of a majority stake in EffRx aligns with Abiogen's growth strategy, serving as a springboard for international expansion and reinforcing its commitment to addressing osteoarticular and bone metabolism diseases. EffRx Pharmaceuticals SA, headquartered in Switzerland, is actively engaged in the treatment of various disorders, including mineral and bone disorders.

Major companies operating in the mineral and bone disorder treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Eli Lilly And Company, Amgen Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Servier Laboratories Pty Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Zydus Cadila Healthcare Ltd., Alembic Pharmaceuticals Limited, Ajanta Pharma Ltd., Abiogen Pharma Spa, Melinta Therapeutics Inc., Intas Pharmaceuticals Ltd., Radius Health Inc., EffRx Pharmaceuticals SA.

North America was the largest region in the mineral and bone disorder treatment market in 2024. The regions covered in mineral and bone disorder treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mineral and bone disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mineral and bone disorder treatment market consists of revenues earned by entities by providing services such as treatment planning, patient education and support and multidisciplinary care. The market value includes the value of related goods sold by the service provider or included within the service offering. The mineral and bone disorder treatment market also includes sales of biphosphates, estrogens, phosphate binders, non-calcium, non-metal-based binders, magnesium-based binders, parathyroid hormone therapy, RANKL (receptor activator of nuclear factor kappa-Β ligand) inhibitors and orthopedic implants which are used in providing mineral and bone disorder treatment-related services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Mineral and bone disorder treatment is a therapeutic approach recommended when there is an imbalance in the levels of calcium and phosphorus in the bloodstream. This treatment is aimed at regulating specific minerals and hormones in the blood to prevent damage to the bones and blood vessels.

The key treatments for mineral and bone disorders encompass dietary adjustments, nutritional interventions, medications, the use of supplements, and, in severe cases, dialysis. Dietary modifications involve consuming foods and beverages that promote bone health, reducing the risk of conditions like osteoporosis and mitigating further bone loss. These treatments can be made available through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and are tailored to different end users, such as hospitals, homecare settings, specialty clinics, and more.

The mineral and bone disorder treatment market research report is one of a series of new reports that provides mineral and bone disorder treatment market statistics, including mineral and bone disorder treatment industry global market size, regional shares, competitors with a mineral and bone disorder treatment market share, detailed mineral and bone disorder treatment market segments, market trends and opportunities and any further data you may need to thrive in the mineral and bone disorder treatment industry. This mineral and bone disorder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.